Comment

  • 15 October 2018

    Roche makes a cautious investment in Ionis’ dAMD drug

    Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx,...

  • 15 October 2018

    ESMO 2018: previewing high-impact, late-breaking abstracts

    The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical...

  • 11 October 2018

    Almirall brings new drug to stagnant US acne market

    On October 2, the FDA approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older. Seysara was originally...